Residency · Residency · Family Medicine

Type 1 Diabetes and Insulin Management Principles

Introduction

Type 1 diabetes mellitus (T1DM) is an autoimmune disease resulting in destruction of pancreatic beta cells and absolute insulin deficiency. It accounts for 5 to 10% of all diabetes cases and requires lifelong insulin therapy. While often diagnosed in childhood, up to 50% of cases present in adulthood, sometimes misdiagnosed as type 2 diabetes. Family physicians must understand insulin physiology, regimen design, and the unique complications of T1DM.

Pathophysiology

The disease involves autoimmune destruction of beta cells mediated by T-lymphocytes. Genetic susceptibility is strongly associated with HLA-DR3 and HLA-DR4. Environmental triggers such as viral infections and dietary factors may initiate autoimmunity in genetically predisposed individuals. Clinical diabetes manifests when 80 to 90% of beta cell mass is destroyed. Autoantibodies, including GAD65, IA-2, ZnT8, and insulin autoantibodies (IAA), are present in 85 to 90% of patients at diagnosis.

Diagnosis

Classic Presentation

The classic presentation involves acute onset of polyuria, polydipsia, weight loss, and fatigue over days to weeks. Diabetic ketoacidosis (DKA) is the presenting feature in 25 to 40% of newly diagnosed cases. Patients are typically young and lean without features of metabolic syndrome.

Distinguishing T1DM from T2DM

Latent Autoimmune Diabetes in Adults (LADA)

LADA is autoimmune diabetes presenting after age 30 that initially may not require insulin, leading to misdiagnosis as T2DM. LADA should be suspected when a lean adult with "type 2 diabetes" has a poor response to oral agents. GAD65 antibodies and C-peptide testing confirm the diagnosis.

Insulin Physiology and Types

Physiologic Insulin Secretion

Normal insulin secretion has two components. Basal insulin provides low-level continuous secretion that suppresses hepatic glucose output between meals and overnight. Bolus (prandial) insulin is a rapid surge in response to meals, matching carbohydrate intake.

Insulin Preparations

Insulin Regimens

Basal-Bolus (Multiple Daily Injections, MDI)

The basal-bolus regimen is the gold standard for T1DM management. The basal component uses glargine or detemir once or twice daily, comprising approximately 40 to 50% of the total daily dose. The bolus component uses rapid-acting insulin before each meal, dosed using an insulin-to-carbohydrate ratio (ICR) and correction factor (CF). A typical starting dose is 0.4 to 0.5 units per kg per day, split 50% basal and 50% bolus.

Insulin Pump Therapy (CSII)

Insulin pump therapy delivers rapid-acting insulin continuously with programmable basal rates and patient-activated boluses. Advantages include flexible dosing, reduced hypoglycemia, and improved HbA1c. It requires motivated, engaged patients willing to learn carbohydrate counting and device management. Hybrid closed-loop systems, such as the Medtronic 780G, Tandem Control-IQ, and Omnipod 5, automate basal adjustments based on continuous glucose monitoring data.

Continuous Glucose Monitoring (CGM)

CGM provides real-time glucose readings every 1 to 5 minutes using devices such as the Dexcom G7, FreeStyle Libre 3, and Medtronic Guardian. The key metric is time in range (TIR), targeting glucose between 70 and 180 mg/dL for more than 70% of the time. CGM reduces HbA1c by 0.3 to 0.5% and significantly decreases hypoglycemia. It is now considered standard of care for all patients with T1DM and dramatically improves quality of life.

Carbohydrate Counting and Dose Calculation

The insulin-to-carbohydrate ratio (ICR) specifies 1 unit per a given number of grams of carbohydrate, commonly starting at 1:10 to 1:15. The correction factor (CF) specifies how much 1 unit lowers glucose, commonly calculated using the 1800 rule (1800 divided by the total daily dose). The bolus dose equals the total carbohydrates divided by the ICR plus the difference between the current glucose and target glucose divided by the CF. The ICR and CF are adjusted based on post-meal glucose patterns, with a 2-hour post-meal target of less than 180 mg/dL.

Glycemic Targets

The HbA1c target is less than 7.0% for most adults, individualized to less than 6.5% for some and less than 8.0% for those with hypoglycemia unawareness. Fasting glucose should be 80 to 130 mg/dL, and 2-hour post-meal glucose should be less than 180 mg/dL. For CGM metrics, more than 70% of time should be spent between 70 and 180 mg/dL, with less than 4% below 70 mg/dL and less than 1% below 54 mg/dL.

Acute Complications

Hypoglycemia

Mild hypoglycemia involves glucose below 70 mg/dL with adrenergic symptoms such as tremor, sweating, and tachycardia, treated with the 15-15 rule (15 g of fast-acting carbohydrates, recheck in 15 minutes). Severe hypoglycemia requires assistance from another person and may involve altered consciousness or seizure. Treatment for severe episodes uses glucagon administered intramuscularly, intranasally, or subcutaneously. Hypoglycemia unawareness, characterized by loss of warning symptoms after recurrent lows, is treated with strict hypoglycemia avoidance for 2 to 3 weeks to restore awareness.

Diabetic Ketoacidosis (DKA)

DKA is triggered by insulin omission, illness, or pump failure. The triad consists of hyperglycemia (greater than 250 mg/dL), metabolic acidosis (pH less than 7.3, bicarbonate less than 18), and ketonemia or ketonuria. Treatment involves IV fluids, IV insulin infusion, potassium replacement, and close monitoring. Sick day rules should be taught to all patients: never stop basal insulin, check blood glucose and ketones every 2 to 4 hours, and increase fluid intake.

Chronic Complications and Screening

Retinopathy screening with annual dilated eye exams begins 5 years after diagnosis or at puberty. Nephropathy is screened with annual urine albumin-to-creatinine ratio and serum creatinine. Neuropathy screening involves annual monofilament examination. Cardiovascular risk is assessed with lipid panel and blood pressure management, with statin therapy recommended for patients over 40 or with risk factors. Annual TSH screening is important because autoimmune thyroiditis is common in T1DM. Celiac disease should be screened for at diagnosis with tissue transglutaminase IgA.

Key Clinical Pearls

Basal insulin should never be withheld in a patient with T1DM, even if they are not eating, because basal insulin prevents DKA. LADA should be suspected in lean adults who present as type 2 diabetes but rapidly fail oral agents; GAD65 antibodies and C-peptide testing confirm the diagnosis. Continuous glucose monitoring is now standard of care for T1DM and should be offered to all patients, as it reduces both HbA1c and hypoglycemia. The 1800 rule (1800 divided by the total daily dose) provides a starting correction factor that is then adjusted based on individual response. Every patient with T1DM should have glucagon prescribed, and family members or close contacts should know how to administer it.

References

1. American Diabetes Association. (2024). Standards of care in diabetes. Diabetes Care, 47(Suppl 1), S1-S321.
2. Holt, R. I. G., et al. (2021). The management of type 1 diabetes in adults: A consensus report by ADA and EASD. Diabetes Care, 44(11), 2589-2625.
3. Beck, R. W., et al. (2017). Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes. JAMA, 317(4), 371-378.
4. Battelino, T., et al. (2019). Clinical targets for continuous glucose monitoring data interpretation. Diabetes Care, 42(8), 1593-1603.

Read this lecture as Markdown